Objective: To determine whether plasma N-terminal probrain natriuretic peptide (NT-proBNP) in premature infants could identify hemodynamically significant patent ductus arteriosus (HsPDA) and to determine the correlation between serial plasma NT-proBNP and echocardiographic assessment of ductal shunting.
Introduction
It is of vital importance to recognize and properly treat hemodynamically significant patent ductus arteriosus (HsPDA) in preterm infants. PDA has been reported to be associated with morbidities in preterm infants as a result of ductal steal from systemic circulation, for example, pulmonary congestion, pulmonary hemorrhage, bronchopulmonary dysplasia, intraventricular hemorrhage and necrotizing enterocolitis. [1] [2] [3] [4] Strategies for PDA closure involve prophylactic treatment, presymptomatic treatment for non-HsPDA, and treatment for HsPDA. 5, 6 Although prophylactic treatment with indomethacin reduces incidence of PDA and severe intraventricular hemorrhage in preterm infants, 7, 8 there are no differences in mortality and long-term neurodevelopment. 9, 10 Recent studies have shown that only one-third of very low birth weight infants develops significant PDA. 10, 11 Therefore, a number of infants, whose PDA would otherwise close spontaneously, will be exposed to the treatment unnecessarily if prophylaxis strategy is used. Clinical assessment for the diagnosis of PDA has been shown to be specific, but not sensitive. [12] [13] [14] Echocardiography is used to detect PDA and to assess the degree of shunting through various cardiac indices, for example, left atrium to aortic root ratio (LA/Ao ratio), left ventricular size or left ventricular output. 15 However, its availability is limited, particularly in developing countries.
Brain natriuretic peptide (BNP) is one of the natriuretic peptides. It is mainly synthesized by cardiac myocytes in atria and ventricles in response to volume expansion or pressure overload to the heart. Pro-peptide (pro-BNP) is metabolized into active form (BNP) and biologically inactive N-terminal end (NT-proBNP). 16 BNP has a half-life of 20 min, whereas NT-proBNP has a longer half-life of 90 min. In addition, NT-proBNP has no circadian variation and remains stable in blood sample. Therefore, it can be kept for later analysis and may serve as a better marker than BNP for assessment of ventricular dysfunction and volume overload. 17 BNP binds to the natriuretic peptide receptor type A causing increased intracellular guanosine monophosphate production. 18, 19 The biological effects of BNP include diuresis, vasodilatation, inhibition of renin and aldosterone production and of cardiac and vascular myocyte growth. Whether NT-proBNP has any biological effect on its own is currently unknown. BNP and NT-proBNP have been used to evaluate congestive heart failure, myocardial dysfunction, or cardiomyopathy. [20] [21] [22] [23] Studies in adults have shown that NT-proBNP is a more sensitive and more specific marker for ventricular dysfunction than the biologically active BNP. 24, 25 Previous studies in healthy full-term infants showed that the plasma BNP level rapidly rises after birth, reaching its peak at day 2-3 of life [26] [27] [28] and a high plasma BNP level correlates with HsPDA. A decline of BNP level is noted after PDA is closed by indomethacin. [29] [30] [31] [32] As the clinical usefulness of NT-proBNP in preterm infants is limited, our objectives were to determine whether plasma NT-proBNP level would help diagnose PDA, and to determine the correlation between NT-proBNP level and echocardiographic parameters of PDA shunting.
Methods
This prospective cohort study was conducted at the Neonatal Intensive Care Unit (NICU), Ramathibodi Hospital, Bangkok, between February 2005 and March 2006. The inclusion criteria for this study were preterm infants, gestational age less than 33 weeks, who were admitted to the NICU within 24 h after birth. Exclusion criteria included congenital heart defects, major congenital anomalies, birth asphyxia with Apgar score at 5 min less than 3, clinical sepsis or septicemia, necrotizing enterocolitis, renal failure, persistent pulmonary hypertension and those administered with indomethacin or ibuprofen before blood specimen collection for NT-proBNP determination. All enrolled infants received standard NICU care; both specific and supportive treatment. The amount of fluid intake was adjusted according to body weight changes allowing for physiologic weight loss and to maintain normal urine output and serum electrolyte.
This study was approved by the institutional review board, and written consent for participation was obtained from the parents or guardians.
Measurement of plasma NT-proBNP
Blood samples (1.0 ml) for plasma NT-proBNP were collected at 48, 96 and 168 h of life by arterial or venous catheter aspiration or by venous blood sampling. Blood samples were sent immediately to the Central Laboratory of the Hospital for analysis, and if not possible, were kept in the refrigerator no more than 24 h. Plasma NT-proBNP was measured using electrochemiluminescence immunoassay technique (Elecsys proBNP; Roche Diagnostics, Germany). The measuring range was 5-35 000 pg ml À1 with a coefficient of variation of 2.2-5.8% and cross reactivity with BNP, and atrial natriuretic peptide of less than 0.001%.
Echocardiography
A two dimensions, color Doppler, and M-mode echocardiogram was performed within 6 h of the time of plasma NT-proBNP collection or whenever symptomatic PDA was suspected. Echocardiographic parameters representing the degree of PDA shunting and volume load included PDA diameter detected by two dimensions and color Doppler, the LA/Ao ratio detected by M-mode, and the left atrium volume index (LAV index) calculated by the prolate ellipse method requiring measurement of LA dimensions from the parasternal long axis view (D1) and apical four chamber view (D2 and D3) and equal to (D1 Â D2 Â D3 Â 0.523)/body surface area. 33 Diagnosis and management of PDA HsPDA was diagnosed by the ductal flow with predominant left to right shunt on color Doppler which measured at least 1.5 mm on two-dimensional echocardiography 34 plus at least two of the following signs, including heart murmur, persistent tachycardia (heart rate >160 min À1 ), hyperactive precordium, bounding pulse, pulse pressure >25 mm Hg, hepatomegaly, pulmonary hemorrhage (defined as blood or blood-stained fluid aspirated from the endotracheal tube in association with a respiratory deterioration and radiographic evidence of pulmonary hemorrhage), increasing respiratory support by 20% increase in oxygen supplementation or in pressure support and chest radiographic evidence of cardiomegaly or pulmonary congestion.
Indomethacin or ibuprofen was administered after HsPDA had been diagnosed. The selection of medication was based on the discretion of the physician. The initial dose of indomethacin was 0.2 mg kg À1 , followed by two additional doses of 0.1 mg kg À1 given intravenously at 12-h intervals. For ibuprofen, the initial dose of 10 mg kg À1 was followed by two additional doses of 5 mg kg
À1
given orally at 24-h intervals.
Statistical analysis
Data collections included body weight changes, fluid intake and output, respiratory and cardiovascular status and echocardiographic parameters of ductal shunting. The attending physicians were unaware of the plasma NT-proBNP values. To compare HsPDA group and non-PDA group, w 2 -test or Fisher's exact test was used for categorical variables. Student's t-test was used for continuous variables or Mann-Whitney U-test if the data were not normally distributed. Pearson's correlation coefficient was used to test for correlation between plasma NT-proBNP level and LA/Ao ratio, LAV index and PDA diameter. The receiver operator characteristic (ROC) curve was used to select the best cut-off point for detection of HsPDA. P-value less than 0.05 was considered statistical significance.
Results
There were 52 infants, born at less than 33 weeks of gestation during the study period: 5 died within 2 days after birth, 2 were expected to die within a few days due to extreme prematurity (<24 weeks of gestation), 4 were referred to our NICU after 2 days of age, and 2 had severe birth asphyxia. Therefore, 39 infants were eligible for the study and 4 of these infants were excluded (2 due to early septic shock and 2 due to indomethacin treatment before blood sampling for NT-proBNP).
Of 35 enrolled infants, 12 had HsPDA and received indomethacin or ibuprofen with a closure rate of 66.7% (8/12). Thus, four infants in this group received the second course of indomethacin resulting in ductus closure in all infants. Total of 23 infants were in non-HsPDA group; 20 infants had no ductus detected by echocardiogram on day 2 and still remained closed thereafter, whereas the other 3 infants in this group had asymptomatic PDA detected by flow across the ductus. On day 4 of life, two out of three infants had spontaneous PDA closure, whereas the remaining infant still had a small PDA and received one course of indomethacin per the discretion of the primary physician.
The characteristics of these two groups are summarized in Table 1 . There were no significant differences observed in gestational age, gender, delivery type, Apgar scores at 1 and 5 min and the use of antenatal steroid. No maternal indomethacin tocolysis was used during the study period and no infants developed sepsis during the first 7 days of life. The infants in the HsPDA group had a significantly lower birth weight and more respiratory distress syndrome, and received lower total fluid in the first 24 h of life.
Echocardiographic results and clinical findings of HsPDA
Compared with the non-HsPDA group, infants in HsPDA group had larger PDA diameter (2.7 ± 1.1 vs 1.2 ± 0.3 mm, P<0.01) and significant more magnitude of shunting indices (mean LA/Ao ratio of 1.62 ± 0.5 vs 1.12 ± 0.2, P<0.01; mean LAV index of 9.5 ± 4.9 vs 3.9±1.6 ml 3 m À2 , P ¼ 0.02). Systolic ejection murmur (SEM) and wide pulse pressure were the most common clinical findings detected in HsPDA infants and occurred in approximately 50% of the cases (Table 2) . Nine infants (75%) developed two signs of these findings at time of being diagnosed with HsPDA. The combination of more specific signs of HsPDA such as hyperactive precordium, wide pulse pressure, bounding pulse or SEM occurred only in three infants (25%).
NT-proBNP and hemodynamic PDA In non-HsPDA group, the plasma level of NT-proBNP was found to peak in the first 2 days of life and then declined during day 4-7 after birth. Plasma NT-proNBP levels on day 2 of infants in the HsPDA group were significantly higher than those in non-HsPDA group with a median of 16 353 pg ml À1 (interquartile range (IQR), 12 360-33 459; range, 10 316-104 998) vs 3914 pg ml À1 (IQR, 2601-5782; range, 1535-19 516) (P<0.001), respectively ( Figure 1) . In non-HsPDA subgroup, the plasma NT-proBNP level on day 2 of three infants with asymptomatic PDA (range, 185-972 pg ml À1 ) were comparable to the levels of 20 infants with no PDA (range, 182-2308 pg ml À1 ). Abbreviations: PDA, patent ductus arteriosus.
NT-proBNP and PDA in preterm infants P Nuntnarumit et al Total of 9 out of 12 infants in HsPDA group received treatment with indomethacin and 3 with ibuprofen. Eight infants responded to the treatment and their NT-proBNP levels declined rapidly within 48 h after treatment. In contrast, NT-proBNP levels of infants who did not respond to the treatment were persistently elevated or slightly decreased (Figure 2 ). The median (range) change of NTproBNP level between day 2 and day 4 was significantly greater in the responders than in the nonresponders (19 764 (9514-93 940) vs 2985 (812-8186) pg ml À1 , P ¼ 0.007). Plasma NT-proBNP levels on day 2 correlated with LA/Ao ratio and LAV index with the Pearson's correlation coefficient of 0.77 and 0.61, respectively (Figure 3) . The multiple regression analysis was used to determine the relationship among NT-proBNP level on day 2 and relevant variables, including gestational age, birth weight, 1-and 5 min Apgar scores, fluid intake during the first 2 days of life, LA/Ao ratio and LAV index. The LA/Ao ratio was the only significant independent variable in the model with R 2 ¼ 0.59, P<0.001.
Using the ROC curve, the cut-off level of NT-proBNP on day 2 at 10 180 pg ml À1 offered the best predictive values for HsPDA with a sensitivity of 100%, a specificity of 91.3%, a positive predictive value of 86.7% and a negative predictive value of 100%. The area under curve was 0.964 (95% confidence interval; 0.906-1.022, P<0.001).
Discussion
This study demonstrated that plasma NT-proBNP levels in premature infants were strongly related to hemodynamic status of PDA. NT-proBNP levels on the second day after birth of HsPDA infants were significantly higher than those of non-HsPDA infants. In addition, the levels declined rapidly within 24-48 h in infants who responded to the indomethacin or ibuprofen therapy, whereas the levels remained the same or slightly decreased in nonresponders.
Plasma concentration of BNP and NT-proBNP is approximately equal in normal subjects; NT-proBNP plasma concentration is 2-10 times higher than BNP in patients with heart failure. This relative change in peptide levels may be explained by shifts in cardiac secretion and/or clearance mechanisms. 19 Previous studies showed that plasma concentration of BNP is high in the first few days after birth due to changes in circulatory volume leading to increased ventricular volume and pressure load. 27, 28 In this study, it is suggested that the peak of plasma NT-proBNP level was in the first 48 h of life and then declined rapidly within the first 7 days, except for those with HsPDA in which NT-proBNP levels were approximately 5-8 times higher. Our findings suggest that physiological changes of NT-proBNP follow the pattern of BNP changes.
El-Khuffash et al. 35 reported a significantly high level of NT-proBNP at 48 h of age, not at 12 h, in preterm infants with HsPDA and a rapid decrease after successful PDA closure. FarombiOghuvbu et al. 36 studied serial plasma NT-proBNP levels on day 1, 3, 5 and 10 of life among 49 infants <34 weeks of gestation and found that the plasma NT-proBNP levels on day 3 and day 5, not on day 1 or day 10, were significantly higher in infants with HsPDA. These findings as well as ours suggest that the best timing to measure NT-proBNP level for predicting HsPDA should be at day 2-3 of life. Recent studies showed that the NT-proBNP level on day 1 of life was affected by gestational age with the level being higher in the more premature infants. High levels of NT-proBNP on day 10 were also found in infants with sepsis. 36 Therefore, high levels of NT-proBNP should be interpreted with caution. In our study, no infants developed clinical sepsis during the first week of life; high levels of NT-proBNP represent an influence of PDA status.
In our study, LA/Ao ratio correlated with the plasma NT-proBNP level after adjusting for other related variables. The previous study 35 has also shown that NT-proBNP on day 3 significantly correlated with LA/Ao ratio, PDA diameter and descending aorta end-diastolic velocity, whereas the other study 37 reported that NT-proBNP at 12 h of age significantly correlated with respiratory distress syndrome and LA:Ao ratio, but not with ductal diameter and a negative correlation was seen between NT-proBNP and left ventricular mean velocity of circumferencetial fiber shortening and shortening fraction. The conflicting results in the degree of correlation between plasma level and related variables may reflect the differences in the postnatal age at time of measurement.
Using the ROC curve, the cut-off plasma NT-proBNP level on day 2 at 10 180 pg ml À1 offered the best predictive values for HsPDA. These results were similar to those of the recent study using NT-proBNP on day 3 as a marker for HsPDA in preterm infants. 36 Interestingly, infants in the HsPDA group exhibited only a few clinical signs of PDA, most of which were nonspecific (Table 2) . Therefore, the NT-proBNP level on day 2-3 may be used as a screening tool in preterm infants for predicting HsPDA and guiding physicians to consider early echocardiographic evaluation. A recent report in preterm <32 weeks of gestation by El-Khuffash et al.
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showed that high NT-proBNP levels at 48 h predict death before discharge or severe intraventricular hemorrhage in infants with a PDA. NT-proBNP in conjunction with an echocardiography may identify preterm infants with PDA who are at risk for poor outcome and would benefit from targeted medical treatment of PDA. In addition, serial NT-proBNP measurements may provide useful information on the response to the treatment because the level of NT-proBNP of most responders significantly decreased within 48 h after treatment (Figure 2 ).
In conclusion, plasma NT-proBNP level peaked during the first few days after birth and declined rapidly within a week. Significantly high levels of plasma NT-proBNP on day 2 were observed in infants who developed HsPDA. Therefore, its level may have a role as a screening tool to predict HsPDA and provide more information regarding the response to the treatment. NT-proBNP and PDA in preterm infants P Nuntnarumit et al
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